Universe Pharmaceuticals INC Announces Pricing and Trading of Initial Public Offering
March 23 2021 - 8:50AM
Universe Pharmaceuticals INC (the “Company”), a pharmaceutical
producer and distributor in China, today announced the pricing of
its initial public offering (“Offering”) of 5,000,000 ordinary
shares at a public offering price of US$5.00 per ordinary share.
The ordinary shares have been approved for listing on the Nasdaq
Global Market and commenced trading today under the ticker symbol
“UPC”.
The Company expects to receive aggregate gross
proceeds of US$25 million from this Offering, before deducting
underwriting discounts and other related expenses. In addition, the
Company has granted the underwriter a 45-day option to purchase up
to an additional 750,000 ordinary shares at the public offering
price, less underwriting discounts. The Offering is expected to
close on or about March 25, 2021, subject to the satisfaction of
customary closing conditions.
Proceeds from the Offering will be used for
upgrading and expanding the Company’s manufacturing facilities,
conducting research and development, branding, advertising and
marketing, and for working capital and general corporate
purposes.
The Offering is being conducted on a firm
commitment basis. Univest Securities, LLC is acting as the
underwriter and book-running manager for the Offering. Hunter
Taubman Fischer & Li LLC is acting as counsel to the Company,
and Pryor Cashman LLP is acting as counsel to Univest Securities,
LLC in connection with the Offering.
A registration statement on Form F-1 relating to
the Offering was filed with the Securities and Exchange Commission
(“SEC”) (File Number: 333-248067) and was declared effective by the
SEC on March 22, 2021. The Offering is being made only by means of
a prospectus, forming a part of the registration statement. Copies
of the final prospectus relating to the Offering may be obtained
from Univest Securities, LLC, by email at IBAssistDesk@univest.us
or standard mail to Univest Securities, LLC, Attn: 375 Park Avenue,
15th Floor, New York, NY 10152. In addition, a copy of the
prospectus relating to the Offering may be obtained via the SEC's
website at www.sec.gov.
Before you invest, you should read the
prospectus and other documents the Company has filed or will file
with the SEC for more complete information about the Company and
the Offering. This press release does not constitute an offer to
sell, or the solicitation of an offer to buy any of the Company’s
securities, nor shall such securities be offered or sold in the
United States absent registration or an applicable exemption from
registration, nor shall there be any offer, solicitation or sale of
any of the Company’s securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of such
state or jurisdiction.
About Universe Pharmaceuticals INC
Universe Pharmaceuticals INC, headquartered in
Ji’an, Jiangxi, China, is a pharmaceutical producer and distributor
in China. The Company specializes in the manufacturing, marketing,
sales and distribution of traditional Chinese medicine derivatives
products targeting the elderly with the goal of addressing their
physical conditions in the aging process and to promote their
general well-being. The Company also distributes and sells
biomedical drugs, medical instruments, Traditional Chinese Medicine
Pieces, and dietary supplements manufactured by third-party
pharmaceutical companies. Currently, the Company’s products are
sold in 30 provinces of China. For more information, visit the
company’s website at http://www.universe-pharmacy.com/.
About Univest Securities,
LLC
Registered with FINRA since 1994, Univest
Securities, LLC provides a wide variety of financial services to
its institutional and retail clients globally including brokerage
and execution services, sales and trading, market making,
investment banking and advisory, wealth management. It strives to
provide clients with value-add service and focuses on building
long-term relationship with its clients. For more information,
please visit: www.univest.us.
Forward-Looking Statements
All statements other than statements of
historical fact in this announcement are forward-looking
statements, including but not limited to, the Company's proposed
Offering. These forward-looking statements involve known and
unknown risks and uncertainties and are based on current
expectations and projections about future events and financial
trends that the Company believes may affect its financial
condition, results of operations, business strategy and financial
needs, including the expectation that the Offering will be
successfully completed. Investors can identify these
forward-looking statements by words or phrases such as "may,"
"will," "expect," "anticipate," "aim," "estimate," "intend,"
"plan," "believe," "potential," "continue," "is/are likely to" or
other similar expressions. The Company undertakes no obligation to
update forward-looking statements to reflect subsequent occurring
events or circumstances, or changes in its expectations, except as
may be required by law. Although the Company believes that the
expectations expressed in these forward-looking statements are
reasonable, it cannot assure you that such expectations will turn
out to be correct, and the Company cautions investors that actual
results may differ materially from the anticipated results and
encourages investors to review other factors that may affect its
future results in the Company’s registration statement and in its
other filings with the SEC.
For more information, please
contact:
Ascent Investors Relations
LLCTina Xiao PresidentPhone:
917-609-0333Email: tina.xiao@ascent-ir.com
Universe Pharmaceuticals (NASDAQ:UPC)
Historical Stock Chart
From Oct 2024 to Nov 2024
Universe Pharmaceuticals (NASDAQ:UPC)
Historical Stock Chart
From Nov 2023 to Nov 2024